Abstract
Background: Until recently, treatment of hypothyroidism has been accomplished using monotherapy of synthetic L-thyroxine (L-T4) sodium tablets that should be taken 30-60 minutes before breakfast. Nowadays, a liquid preparation of levothyroxine is available and can effectively replace tablets without the need of waiting before having breakfast. Evidence of Quality of life (QoL) improvement when shifting from the former to the latter preparation, however, is still lacking.
Objective: The study aimed to assess changes in QoL of hypothyroid patients dissatisfied with their therapy with L-T4 sodium tablets who were switched from tablets taken 30-60 minutes before breakfast to liquid L-T4 at breakfast.
Methods: A total of 418 consecutive hypothyroid subjects treated by means of L-T4 tablets were asked about their satisfaction/dissatisfaction in order to take the medication 30-60 minutes before having breakfast. Overall, 110 patients (26.3%) complained of the timing of their L-T4 therapy (30-60 minutes before breakfast). A dedicated QoL questionnaire (ThyTSQ), taking just a few minutes to be filled in was then administered to these dissatisfied patients. They were therefore switched to L-T4 to be taken at breakfast. Aiming to avoid TSH elevation due to L-T4 tablets malabsorption caused by meal interference and gastric pH changes, patients were invited to take L-T4 liquid form, as this is claimed to be scarcely affected by the non-fasting state. The questionnaire (ThyTSQ) was administered again at the control visit 3 months later. TSH, FT4, FT3 serum concentrations and metabolic parameters were also recorded.
Results: An improved QoL, mainly due to an easier adherence to treatment, was reported by 66.6% of 102 patients who completed the study after shifting from taking medication 30-60 minutes before breakfast to at breakfast ingestion (P<0.01). An overall 10.7% of patients found the liquid formulation distasteful. Mean values of TSH, FT4, FT3, and of metabolic parameters did not significantly change but in eight patients (7.7%) who showed a TSH increase > 2mIU/L.
Conclusion: In hypothyroid subjects dissatisfied with L-T4 tablets ingested 30-60 minutes before breakfast, the shift to the same dose of L-T4 in liquid form taken at breakfast improved QoL in the majority of patients, without affecting thyroid function.
Keywords: Hypothyroidism, Quality of Life, Levothyroxine, replacement therapy, TSH, monotherapy.
Graphical Abstract
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Shift from Levothyroxine Tablets to Liquid Formulation at Breakfast Improves Quality of Life of Hypothyroid Patients
Volume: 18 Issue: 3
Author(s): Rinaldo Guglielmi, Franco Grimaldi, Roberto Negro, Andrea Frasoldati, Irene Misischi, Filomena Graziano, Claudia Cipri, Edoardo Guastamacchia, Vincenzo Triggiani*Enrico Papini
Affiliation:
- Interdisciplinary Department of Medicine, Section of Internal Medicine, Geriatrics, Endocrinology and Rare Diseases. University of Bari ,Italy
Keywords: Hypothyroidism, Quality of Life, Levothyroxine, replacement therapy, TSH, monotherapy.
Abstract: Background: Until recently, treatment of hypothyroidism has been accomplished using monotherapy of synthetic L-thyroxine (L-T4) sodium tablets that should be taken 30-60 minutes before breakfast. Nowadays, a liquid preparation of levothyroxine is available and can effectively replace tablets without the need of waiting before having breakfast. Evidence of Quality of life (QoL) improvement when shifting from the former to the latter preparation, however, is still lacking.
Objective: The study aimed to assess changes in QoL of hypothyroid patients dissatisfied with their therapy with L-T4 sodium tablets who were switched from tablets taken 30-60 minutes before breakfast to liquid L-T4 at breakfast.
Methods: A total of 418 consecutive hypothyroid subjects treated by means of L-T4 tablets were asked about their satisfaction/dissatisfaction in order to take the medication 30-60 minutes before having breakfast. Overall, 110 patients (26.3%) complained of the timing of their L-T4 therapy (30-60 minutes before breakfast). A dedicated QoL questionnaire (ThyTSQ), taking just a few minutes to be filled in was then administered to these dissatisfied patients. They were therefore switched to L-T4 to be taken at breakfast. Aiming to avoid TSH elevation due to L-T4 tablets malabsorption caused by meal interference and gastric pH changes, patients were invited to take L-T4 liquid form, as this is claimed to be scarcely affected by the non-fasting state. The questionnaire (ThyTSQ) was administered again at the control visit 3 months later. TSH, FT4, FT3 serum concentrations and metabolic parameters were also recorded.
Results: An improved QoL, mainly due to an easier adherence to treatment, was reported by 66.6% of 102 patients who completed the study after shifting from taking medication 30-60 minutes before breakfast to at breakfast ingestion (P<0.01). An overall 10.7% of patients found the liquid formulation distasteful. Mean values of TSH, FT4, FT3, and of metabolic parameters did not significantly change but in eight patients (7.7%) who showed a TSH increase > 2mIU/L.
Conclusion: In hypothyroid subjects dissatisfied with L-T4 tablets ingested 30-60 minutes before breakfast, the shift to the same dose of L-T4 in liquid form taken at breakfast improved QoL in the majority of patients, without affecting thyroid function.
Export Options
About this article
Cite this article as:
Guglielmi Rinaldo , Grimaldi Franco , Negro Roberto , Frasoldati Andrea , Misischi Irene , Graziano Filomena , Cipri Claudia , Guastamacchia Edoardo , Triggiani Vincenzo *, Papini Enrico , Shift from Levothyroxine Tablets to Liquid Formulation at Breakfast Improves Quality of Life of Hypothyroid Patients, Endocrine, Metabolic & Immune Disorders - Drug Targets 2018; 18 (3) . https://dx.doi.org/10.2174/1871530318666180125155348
DOI https://dx.doi.org/10.2174/1871530318666180125155348 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin
CNS & Neurological Disorders - Drug Targets Neuronal Histamine and its Receptors in Obesity and Diabetes
Current Diabetes Reviews Hypomagnesaemia/Hypokalemia Associated with the Use of Esomeprazole
Current Drug Safety Systemic Involvement of IgG4-related Sclerosing Disease
Current Immunology Reviews (Discontinued) Intravitreal Triamcinolone in Diabetic Retinopathy
Current Diabetes Reviews Mucopolysaccharidosis Type II (Hunter Syndrome): Clinical Picture and Treatment
Current Pharmaceutical Biotechnology Involvement of Trace Elements in the Pathogenesis of Prion Diseases
Current Pharmaceutical Biotechnology Natural Agents Modulating ACE-2: A Review of Compounds with Potential against SARS-CoV-2 Infections
Current Pharmaceutical Design Compensating, Controlling, Resigning and Accepting-Older Persons Perception of Physical Decline
Current Aging Science Breath Analysis Using SIFT-MS to Assess Metabolic Status in Patients After Gastro-oesophageal Cancer Surgery- a Pilot Study
Current Analytical Chemistry Emerging Indications for Statins: A Pluripotent Family of Agents with Several Potential Applications
Current Pharmaceutical Design Angiotensin II: Role in Skeletal Muscle Atrophy
Current Protein & Peptide Science Monitoring Calcific Aortic Valve Disease: The Role of Biomarkers
Current Medicinal Chemistry Effects of Peach (Prunus persica)-Derived Glucosylceramide on the Human Skin
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Minimally-Invasive and Non-Invasive Continuous Glucose Monitoring Systems: Indications, Advantages, Limitations and Clinical Aspects
Current Diabetes Reviews Meet the Editorial Board:
Current Drug Targets Treatment of Inflammatory and Paraproteinemic Neuropathies
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Hypoglycaemia and Cardiovascular Disease Risk in Patients with Diabetes
Current Pharmaceutical Design HMGB1-Directed Drug Discovery Targeting Cutaneous Inflammatory Dysregulation
Current Drug Metabolism Maternal Sepsis: Current Approaches to Recognition and Clinical Management
Current Women`s Health Reviews